Home » FDA Grants Fast Track Status to Achillion ACH-1625 Drug
FDA Grants Fast Track Status to Achillion ACH-1625 Drug
Achillion Pharmaceuticals’s ACH-1625 drug has been granted fast track designation by the FDA for the treatment of chronic hepatitis C virus.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May